Oxidative amidation of benzaldehydes and benzylamines with<i>N</i>-substituted formamides over a Co/Al hydrotalcite-derived catalyst
作者:Shyam Sunder R. Gupta、Akhil V. Nakhate、Kalidas B. Rasal、Gunjan P. Deshmukh、Lakshmi Kantam Mannepalli
DOI:10.1039/c7nj03123h
日期:——
The present work describes a highly efficient synthetic strategy for amides via oxidative coupling of benzaldehydes or benzylamines with N-substituted formamides using a heterogeneous Co/Al hydrotalcite-derived catalyst in the presence of TBHP. A series of Co/Al hydrotalcite-derived catalysts (Cat-2, Cat-3, and Cat-4 with the Co2+/Al3+ molar ratio in the synthesis mixture as 1/1, 2/1 and 3/1) have
Facile Access to Amides from Oxygenated or Unsaturated Organic Compounds by Metal Oxide Nanocatalysts Derived from Single-Source Molecular Precursors
作者:Akbar Mohammad、Prakash Chandra、Topi Ghosh、Mauro Carraro、Shaikh M. Mobin
DOI:10.1021/acs.inorgchem.7b01576
日期:2017.9.5
explored for the aforementioned reaction. Also, we have carefully investigated the difference in the catalytic performance of Co-, Ni-, and Cu-based nanoparticles synthesized from the SSMP for the conversion of various oxygenated and unsaturated organic compounds to their respective amides. Among all, CuO showed an optimum catalytic performance for the oxidative amidation of various oxygenated and unsaturated
cis-3,4-chroman derivatives useful in the prevention or treatment of
申请人:Novo Nordisk A/S
公开号:US06043269A1
公开(公告)日:2000-03-28
The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
申请人:Novo Nordisk A/S
公开号:US06316494B1
公开(公告)日:2001-11-13
The present invention relates to therapeutically active compounds of formula I
a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.